UBS initiated coverage of Kaken Pharmaceutical (KKPCF) with a Neutral rating and 4,200 yen price target he firm says the company’s business stability is priced into the shares with limited catalysts ahead.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential